[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
3. Kamura T, Jeon JD: Lymph node metastasis in a gynecologic malignancy. Yonsei Med J; 2002 Dec;43(6):783-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For these patients, many histopathological parameters have been reported to be prognostic factors of cervical cancer, such as a pelvic lymph node (PLN) metastasis, the histological subtype, the tumor diameter, the depth of the stromal invasion, a lymph-vascular space invasion (LVSI), a parametrial invasion, a corpus invasion and a vaginal invasion.
  • Ovarian cancer is normally treated with cytoreductive surgery followed by chemotherapy.
  • [MeSH-minor] Endometrial Neoplasms / pathology. Female. Humans. Lymphatic Metastasis. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12497663.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


Advertisement
4. Nassar OA, Abdul Moaty SB, Khalil el-SA, El-Taher MM, El Najjar M: Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results. J Egypt Natl Canc Inst; 2010 Jun;22(2):113-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results.
  • PURPOSE: Uterine corpus sarcomas are rare heterogeneous tumors characterized by rapid progression and poor response to treatment.
  • This series investigated treatment options, relapse pattern, survival and prognostic factors.
  • Surgery was the primary line of treatment for all cases with total abdominal hysterectomy and bilateral salpingoophorectomy in 88% of cases and 12% had less extensive surgery.
  • Twenty-four (40.7%) patients had surgery alone, 24 (40.7%) had surgery and radiotherapy, 7 (11.9%) had surgery and chemo-irradiation and 4 (6.7%) had surgery and chemotherapy.
  • Stage, adjuvant irradiation, tumor size, myometrial invasion, vascular and cervix invasion were significant factors in univariate analysis; nevertheless, multivariate prognostic factors were only stage (p=0.04) and adjuvant irradiation (p=0.01).
  • Neither extent of surgery, chemotherapy, histologic type or grade had significant effect on survival.
  • Adjuvant radiotherapy offered 62% 2-year cumulative overall survival versus 22% for surgery alone and surgery with chemotherapy.
  • CONCLUSION: Diagnosis of uterine sarcoma is in itself a poor prognostic factor.
  • Complete cytoreductive surgery and adjuvant radiotherapy is essential for local control, provided tumor is limited to the uterus.
  • KEY WORDS: Uterine cancer - Uterine sarcoma - Uterine sarcoma treatment - Sarcoma irradiation - Sarcoma prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21860468.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


5. Erhan Y, Dikmen Y, Yucebilgin MS, Zekioglu O, Mgoyi L, Terek MC: Large cell neuroendocrine carcinoma of the uterine corpus metastatic to brain and lung: case report and review of the literature. Eur J Gynaecol Oncol; 2004;25(1):109-12
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell neuroendocrine carcinoma of the uterine corpus metastatic to brain and lung: case report and review of the literature.
  • Neuroendocrine carcinoma of the uterine corpus is a rare aggressive tumor with a similar unfavorable outcome to that of the cervix.
  • The large cell type is considerably rarer than the small cell neuroendocrine carcinoma of the uterine corpus.
  • We report a case of a 52-year-old woman who presented with a large cell neuroendocrine tumor of the uterine corpus with very aggressive clinical behavior, cerebral and pulmonary metastases six and four months after initial diagnosis and adjuvant radiotherapy, respectively.
  • Despite successful surgical extirpation of the cerebral metastatic lesion she did not respond to chemotherapy and died four months after disease recurrence.
  • [MeSH-major] Brain Neoplasms / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Lung Neoplasms / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15053077.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 31
  •  go-up   go-down


6. Takano M, Shibasaki T, Sato K, Aida S, Kikuchi Y: Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component. Gynecol Oncol; 2003 Nov;91(2):444-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component.
  • OBJECTIVES: Hepatoid adenocarcinoma is a rare tumor and has the histological coexistence of well-differentiated adenocarcinoma and nests of hepatoid cells with immunoreactivity for alpha-fetoprotein (AFP).
  • A case of hepatoid adenocarcinoma in malignant mixed Mullerian tumor of the uterus is presented with a review of the literature.
  • Histologically, the tumor was composed of endometrioid adenocarcinoma, neoplastic hepatoid cells, and sarcoma component including leiomyosarcoma and rhabdomyosarcoma.
  • After operation followed by six courses of platinum-based chemotherapy, serum levels of AFP dropped into normal range.
  • CONCLUSIONS: This is, to our knowledge, the first report of malignant mixed Mullerian tumor of the uterus with an AFP-producing hepatoid adenocarcinoma component.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Mixed Tumor, Mullerian / metabolism. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599882.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 17
  •  go-up   go-down


7. Shah JP, Jelsema J, Bryant CS, Ali-Fehmi R, Malone JM Jr: Carboplatin and paclitaxel adjuvant chemotherapy in primitive neuroectodermal tumor of the uterine corpus. Am J Obstet Gynecol; 2009 Feb;200(2):e6-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin and paclitaxel adjuvant chemotherapy in primitive neuroectodermal tumor of the uterine corpus.
  • Primitive neuroectodermal tumor of the uterine corpus (PNET) is rare and appears to have an aggressive clinical course.
  • We report on a postmenopausal woman with optimal surgically cytoreduced advanced-stage PNET in which adjuvant combination chemotherapy with platinum and taxane agents was unsuccessful in extending her disease-free survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neuroectodermal Tumors, Primitive / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Middle Aged. Paclitaxel / administration & dosage. Postmenopause. Radiotherapy, Adjuvant. Uterine Hemorrhage / etiology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110219.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 25
  •  go-up   go-down


8. Goudy G, Stoeckle E, Thomas L, Kind M, Guyon F, Brouste V, Floquet A: [Prognostic impact of tumour volume and lymph node involvement in intermediate stage T1b1 to T2b cancer of the uterine cervix]. Bull Cancer; 2009 Jun;96(6):685-94
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic impact of tumour volume and lymph node involvement in intermediate stage T1b1 to T2b cancer of the uterine cervix].
  • OBJECTIVE: Determine the prognostic significance of tumour volume and pelvic lymph node status in intermediate stage T1b1 to T2b cancers of the uterine cervix.
  • PATIENTS AND METHODS: Multivariate prognostic factor study in 219 patients (pts), median age 48 years, with stage T1b1 > 2 cm to T2b cervical cancers treated in 91% by primary radio- +/- chemotherapy.
  • RESULTS: Significant prognostic variables in univariate analysis were the ASA anaesthetic score, stage T2b, tumour diameter, involvement of the uterine corpus, radiological (N1) and histological (N+) pelvic lymph node involvement and bilateral N+.
  • Pelvic lymph node involvement should be determined before treatment.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Lymph Node Excision / methods. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Pelvis. Prognosis. Retrospective Studies. Survival Analysis. Tumor Burden. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467961.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Toyoda H, Hirai T, Ishii E: Alpha-fetoprotein producing uterine corpus carcinoma: A hepatoid adenocarcinoma of the endometrium. Pathol Int; 2000 Oct;50(10):847-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein producing uterine corpus carcinoma: A hepatoid adenocarcinoma of the endometrium.
  • On admission a uterine corpus mass and high serum AFP concentration (31950 ng/mL) was noted.
  • Histologically, the biopsy specimen taken from the uterine mass showed a poorly differentiated endometrial carcinoma and a radical hysterectomy was subsequently performed.
  • The postoperative serum AFP value transiently decreased with chemotherapy, however, lung metastases were found and the patient died 12 months following surgery.
  • The resected uterus had a necrotic tumor, 6 x 5 x 4 cm in size, filling the endometrial cavity, characterized by exophytic growth with infiltration in the myometrium.
  • Histologically, the tumor was composed of the main medullary carcinoma area with microcysts and admixed small areas of well-differentiated endometrioid adenocarcinoma, accompanied by a smooth transition with one another.
  • In both the areas, the tumor cells had immunoreactive AFP, alpha-1-antitripsin, albumin, transferrin, carcinoembryonic antigen, CA19-9, and epithelial membrane antigen.
  • There was no histologic evidence for a germ cell tumor.
  • Based on these findings, this uterine corpus tumor was regarded as hepatoid variant of endometrial carcinoma.
  • Although the histogenesis remains controversial, we assume the hypothesis that the tumor may arise in the endometrium per se in association with abnormal differentiation of muellerian duct elements.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Fatal Outcome. Female. Humans. Immunoenzyme Techniques. Magnetic Resonance Imaging. Middle Aged. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11107058.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins
  •  go-up   go-down


10. McAlpine J, Azodi M, O'Malley D, Kelly M, Golenewsky G, Martel M, Rutherford T, Tavassoli F: Extrarenal Wilms' tumor of the uterine corpus. Gynecol Oncol; 2005 Mar;96(3):892-6
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrarenal Wilms' tumor of the uterine corpus.
  • A case of uterine Wilms' tumor in an adult is presented with a review of the literature.
  • She was surgically staged, received chemotherapy, and is without evidence of disease at 1 year follow-up.
  • CONCLUSIONS: Prognosis and treatment of EWT may differ by location and patient age.
  • Literature review of uterine Wilms' tumor reveals favorable outcome with (1) focal disease confined to the uterus and (2) adequate surgery, including hysterectomy.
  • The National Wilms' Tumor Study Group recommends adjuvant chemotherapy for all EWT.
  • [MeSH-major] Uterine Neoplasms / pathology. Wilms Tumor / pathology

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721447.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


11. Inoue M: [Prognostic factors uterine corpus cancer]. Gan To Kagaku Ryoho; 2006 Dec;33(13):2008-13
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors uterine corpus cancer].
  • FIGO staging has taken into consideration of the tumor expansion and is the most important predictor in evaluating patient outcome.
  • Characteristics of tumor biology, such as morphology of tumor and depth of invasion are also important prognostic considerations.
  • Finally, treatment of uterine corpus cancer can be directly related to prognosis.
  • Postoperative chemotherapy is gradually taking precedence over irradiation in considering evidence-based medicine.
  • [MeSH-major] Lymph Nodes / pathology. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197744.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 36
  •  go-up   go-down


12. Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC: Hematogenous dissemination in corpus cancer. Gynecol Oncol; 2001 Feb;80(2):233-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematogenous dissemination in corpus cancer.
  • OBJECTIVE: The aim of this study was to assess the predictors of hematogenous dissemination (HD) in corpus cancer.
  • METHODS: In 612 corpus cancer patients managed surgically, we defined HD as tumor spread to the lung, liver, or other sites via hematogenous routes.
  • RESULTS: We observed 142 instances of tumor spread-71 nonhematogenous and 42 hematogenous to the lung, 9 to the liver, 5 to other sites (adrenals, breast, brain, bone, skin), 3 to both liver and lung, 1 to both lung and bone, and 11 to sites unknown.
  • Stage IV disease, positive adnexae, deep myometrial invasion, primary tumor diameter, tumor involving the whole uterine cavity, positive peritoneal cytology, adjuvant radiotherapy, adjuvant chemotherapy, grade 3 histology, histologic subtype, and lymph-vascular invasion significantly (P < or = 0.01) correlated with HD.
  • CONCLUSIONS: The presence of deep myometrial invasion was the strongest predictor of HD in corpus cancer, and, together with stage IV disease, it independently predicted lung recurrence.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11161865.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA15083
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


13. Mukherjee U, Thakur V, Katiyar D, Goyal HK, Pendharkar D: Uterine choriocarcinoma in a postmenopausal woman. Med Oncol; 2006;23(2):301-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine choriocarcinoma in a postmenopausal woman.
  • Uterine choriocarcinoma developing in patients beyond reproductive age is a rare occurrence.
  • We report a case of choriocarcinoma of uterine corpus in a 54-yr-old woman after 7 yr of menopause and 25 yr after last child birth.
  • She presented with pain in the abdomen, and on radiological investigation a left uterine adnexal mass of 3.4 x 2.8 cm size was detected.
  • Hysterectomy revealed an intramural growth in left uterine cornu measuring 3.5 x 3.0 x 2.5 cm.
  • Histological features of the tumor were consistent with choriocarcinoma, and immunohistochemistry detected strong reactivity for beta-hCG in the tumor cells.
  • The patient was put on combination chemotherapy (EMACO).
  • She achieved serological remission but showed a rise in serum beta-hCG level 4 wk after completion of chemotherapy.
  • We conclude that a high level of suspicion may help in preoperative diagnosis of uterine choriocarcinoma in the postmenopausal age group.
  • However, the response to chemotherapy in these cases may not be as encouraging as in choriocarcinoma of reproductive age.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Choriocarcinoma. Postmenopause. Uterine Neoplasms
  • [MeSH-minor] CA-125 Antigen / blood. Chorionic Gonadotropin, beta Subunit, Human / metabolism. Combined Modality Therapy / methods. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Leucovorin / administration & dosage. Methotrexate / administration & dosage. Middle Aged. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2004 Sep;128(9):1039-42 [15338558.001]
  • [Cites] Ann Pathol. 2003 Oct;23(5):443-6 [14752389.001]
  • [Cites] Gynecol Oncol. 1985 Jan;20(1):53-61 [2981190.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1558-62 [11075860.001]
  • [Cites] Obstet Gynecol. 1978 Apr;51(4):477-88 [662231.001]
  • [Cites] J Reprod Med. 1994 Mar;39(3):217-22 [7518518.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):667-9 [13678743.001]
  • [Cites] Int J Gynecol Cancer. 2002 May-Jun;12(3):312-6 [12060455.001]
  • (PMID = 16720931.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Chorionic Gonadotropin, beta Subunit, Human; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate; EMACO protocol
  •  go-up   go-down


14. Hardisson D, Simón RS, Burgos E: Primary osteosarcoma of the uterine corpus: report of a case with immunohistochemical and ultrastructural study. Gynecol Oncol; 2001 Jul;82(1):181-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary osteosarcoma of the uterine corpus: report of a case with immunohistochemical and ultrastructural study.
  • BACKGROUND: Primary uterine osteosarcoma is extremely rare, with only 15 cases reported in the literature.
  • CASE: A 41-year-old woman presented with abnormal vaginal bleeding due to a large tumor arising from the uterine corpus.
  • Histologically, the tumor showed the features of a malignant mesenchymal neoplasm with osteoid formation and lacked an epithelial component.
  • The tumor was excised and the patient received chemotherapy and radiation therapy postoperatively, but the tumor recurred locally at the 8-month follow-up.
  • CONCLUSION: Osteosarcoma as a primary uterine tumor is exceedingly rare and should be distinguished from carcinosarcoma, which shows different macroscopic and histologic features.
  • Prognosis of this neoplasm is very poor with an average life expectancy of 5 months.
  • [MeSH-major] Osteosarcoma / ultrastructure. Uterine Neoplasms / ultrastructure
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Fatal Outcome. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Proteins / analysis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11426983.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Number-of-references] 15
  •  go-up   go-down


15. Wani Y, Notohara K, Tsukayama C: Mesonephric adenocarcinoma of the uterine corpus: a case report and review of the literature. Int J Gynecol Pathol; 2008 Jul;27(3):346-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesonephric adenocarcinoma of the uterine corpus: a case report and review of the literature.
  • Mesonephric adenocarcinoma (MA) is a rare tumor of the female genital tract, mainly in the cervix and vagina, which is usually associated with mesonephric remnants or mesonephric hyperplasia.
  • In the uterus corpus, MA is as rare as mesonephric structures, and only a few cases have been previously reported.
  • Here, we report a rare case of MA of the uterine corpus.
  • Abdominal computed tomography scan confirmed a uterine tumor measuring 8.6 cm.
  • All tumor markers, including CA125, were within normal limits.
  • The tumor was confined to the myometrium and showed strong resemblance to cervical MA despite the absence of mesonephric hyperplasia or remnants.
  • The most striking pattern consisted of large sheets of small round tubules, often with densely eosinophilic secretions in the lumen.
  • A mixture of tubular and ductal patterns, most predominantly seen, formed more complex tubules and cribriform structures.
  • Immunohistochemically, the tumor cells were positive not only for cytokeratin, epithelial membrane antigen, and vimentin but also for CD10 and calretinin.
  • Adjuvant chemotherapy was begun for the patient, who is alive with disease 28 months later.
  • We review the previously published cases of MA and discuss the principal differential diagnosis of MA in the uterine corpus.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580312.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


16. Chmaj-Wierzchowska K, Wierzchowski M, Szymanowski K, Czerniak T, Mróz M, Sobiak S, Opala T: Pleomorphic rhabdomyosarcoma of the uterine corpus--a case report. Ginekol Pol; 2010 Jul;81(7):541-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic rhabdomyosarcoma of the uterine corpus--a case report.
  • Pleomorphic rhabdomyosarcoma of the uterus is a rare malignant tumor.
  • Vaginal ultrasonography showed enlarged uterus, 82 mm x 64 mm in size.
  • The patient underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy with postoperative chemotherapy due to pleomorphic rhabdomyosarcoma of the uterus.
  • [MeSH-major] Postmenopause. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Female. Humans. Hysterectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20825058.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


17. Kaneyasu Y, Okawa T, Yajima M, Saito R, Nakabayashi M, Seshimo A, Kameoka S, Aomi S, Nishikawa T, Sawada T, Mitsuhashi N: Stage IVB uterine endometrial cancer successfully salvaged by chemoradiotherapy and surgery. Int J Clin Oncol; 2003 Feb;8(1):60-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IVB uterine endometrial cancer successfully salvaged by chemoradiotherapy and surgery.
  • A case of stage IVB adenoacanthoma of the uterine corpus is described.
  • Computed tomography and magnetic resonance imaging revealed a large tumor accompanied by lymph node involvement in the left inguinal, multiple pelvic, and paraaortic regions.
  • Neoadjuvant chemotherapy with carboplatin (CBDCA) and 5-fluorouracil (5-FU) was performed, followed by radiotherapy.
  • The tumor responded very well, but still remained in Douglas' pouch after treatment.
  • Histopathologically, viable cancer cells were observed only in the fundus of the uterus.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy. Salvage Therapy. Uterine Neoplasms / therapy. Uterus / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Magnetic Resonance Imaging. Metaplasia / diagnosis. Metaplasia / therapy. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12601546.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Camatte S, Morice P, Atallah D, Pautier P, Lhommé C, Haie-Meder C, Duvillard P, Castaigne D: Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg; 2002 Sep;195(3):332-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies.
  • BACKGROUND: The aim of this study is to evaluate the rate and the clinical outcomes of lymph node involvement in patients treated for borderline ovarian tumor (BOT).
  • STUDY DESIGN: Forty-two patients were treated for BOT with a procedure that included lymphadenectomy.
  • Thirty-two patients underwent systematic lymphadenectomy, five because of associated cancer (uterine cervix or corpus) and five because of bulky nodes discovered during the surgical procedure.
  • None of the patients with a mucinous tumor had nodal involvement.
  • None of the patients with nodal involvement died of borderline tumor.
  • One patient died of a complication of adjuvant therapy (leukemia after chemotherapy).
  • This procedure should be carried out in patients with serous tumor and enlarged lymph nodes.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Combined Modality Therapy. Cystadenoma, Mucinous / pathology. Cystadenoma, Mucinous / therapy. Cystadenoma, Serous / pathology. Cystadenoma, Serous / therapy. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Neoplasms, Complex and Mixed / pathology. Neoplasms, Complex and Mixed / therapy. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12229940.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Taşkin EA, Taşkin S, Berker B, Erol E, Dünder I, Söylemez F: Aggressive mixed type endometrial carcinoma in a young woman with rapid progression and fatal outcome. Arch Gynecol Obstet; 2008 Jan;277(1):71-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive mixed type endometrial carcinoma in a young woman with rapid progression and fatal outcome.
  • INTRODUCTION: Endometrial carcinoma in young ages is uncommon and tends to be a well differentiated endometrioid type and has an excellent prognosis.
  • Nevertheless, in this report mixed type endometrial cancer including serous, clear cell and endometrioid components in a young patient with rapid progression and fatal outcome is presented.
  • Transabdominal ultrasonography demonstrated 30 x 27 mm intramural mass consistent with leiomyoma in uterine corpus posterior.
  • Mixed type endometrial carcinoma was diagnosed and she was treated with comprehensive surgery plus adjuvant chemotherapy.
  • CONCLUSION: We suggest that persistent uterine bleeding associated with severe anemia should be evaluated for malignancy even in young women to avoid delay in diagnosis.
  • [MeSH-major] Endometrial Neoplasms / pathology. Mixed Tumor, Malignant / pathology
  • [MeSH-minor] Adult. Anemia / etiology. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Menorrhagia / etiology. Neoplasm Invasiveness. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639438.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Terada T: Large cell neuroendocrine carcinoma with sarcomatous changes of the endometrium: a case report with immunohistochemical studies and molecular genetic study of KIT and PDGFRA. Pathol Res Pract; 2010 Jun 15;206(6):420-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 40-year-old woman was admitted to our hospital because of abnormal uterine bleeding.
  • Gynecologic examination and imaging modalities revealed a polypoid tumor of the uterine corpus.
  • Uterine curettage biopsy revealed a sarcomatous undifferentiated carcinoma.
  • The patient was diagnosed as having FIGO stage Ib (T1N0M0) carcinoma, and adjuvant chemotherapy was performed.
  • Pathologically, a polypoid tumor measuring 3x2x2 cm(3) was found in the uterine corpus.
  • Histologically, the tumor consisted of relatively large-sized carcinoma cells without differentiation.
  • The tumor cells have abundant cytoplasm and prominent nucleoli.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20189318.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Stem Cell Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


21. Trimble EL, Harlan LC, Clegg LX, Stevens JL: Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States. Gynecol Oncol; 2005 Mar;96(3):741-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States.
  • METHODS: The Surveillance, Epidemiology, and End-Results Program data were used to sample women newly diagnosed in 1998 with cancer of the corpus uteri.
  • We then sought to verify the therapy provided each woman with her treating physician.
  • RESULTS: Non-Hispanic black women were diagnosed with higher stage, grade, poor histologic subtype, and greater extension of the tumor than were non-Hispanic white women.
  • Hispanic women were diagnosed with more favorable tumor characteristics than non-Hispanic black women, but less favorable than non-Hispanic white women.
  • The use of radiation and chemotherapy increased with stage.
  • CONCLUSIONS: Our study did not show any difference in recommended therapy for women with uterine adenocarcinoma among NH black women, NH white women, and Hispanic women.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy
  • [MeSH-minor] Adult. African Continental Ancestry Group. Aged. Chemotherapy, Adjuvant. European Continental Ancestry Group. Female. Hispanic Americans. Humans. Middle Aged. Neoplasm Staging. Preoperative Care. Radiotherapy, Adjuvant. SEER Program

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721420.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kirk CM, Naumann RW, Hartmann CJ, Brown CA, Banks PM: Primary endometrial T-cell lymphoma. A case report. Am J Clin Pathol; 2001 Apr;115(4):561-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most involve the cervix rather than the uterine corpus.
  • We report the case of a white woman from the United States with a diffuse large cell lymphoma of the endometrium, characterized as a peripheral T-cell type on the basis of immunophenotypic and molecular probe studies.
  • Staging evaluation revealed tumor limited to the endometrium (stage IE).
  • The patient underwent a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection and received 6 cycles of combination chemotherapy, after which she remained free of disease at last follow-up of 36 months.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Hysterectomy. Immunophenotyping. Middle Aged. Neoplasm Staging. Ovariectomy. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11293904.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


23. Delli Carpini J, Karam AK, Montgomery L: Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis; 2010 Mar;13(1):43-58
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer.
  • Tumor neovascularization is a complex process that plays a crucial role in the development of many different types of cancer.
  • By increasing vascular permeability in endothelial cells, it helps tumors recruit wound-healing proteins fibrin and fibrinogen from the plasma, suggesting that tumor formation is a process of abnormal wound healing dependent on the ability to generate a blood supply.
  • The human female reproductive tract is highly dependent on VEGF for normal functions such as endometrial proliferation and development of the corpus luteum.
  • Clinical trials have investigated the humanized monoclonal antibody bevacizumab as potential treatment for all three forms of cancer; the data show that in breast cancer, the use of bevacizumab may lengthen the disease-free survival for women with advanced breast cancer, but does not appear to change their overall survival.
  • It may have a role as salvage chemotherapy for ovarian and cervical cancer, though further research is needed to establish it as a definitive form of treatment.
  • [MeSH-major] Neoplasms / diagnosis. Neoplasms / therapy. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Breast Neoplasms / blood supply. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Female. Humans. Neovascularization, Pathologic / metabolism. Ovarian Neoplasms / blood supply. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Prognosis. Uterine Cervical Neoplasms / blood supply. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Angiogenesis. 2010 Sep;13(3):279. Carpini, Jennifer Delli [corrected to Delli Carpini, Jennifer]
  • (PMID = 20229258.001).
  • [ISSN] 1573-7209
  • [Journal-full-title] Angiogenesis
  • [ISO-abbreviation] Angiogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 105
  •  go-up   go-down


24. Ishibashi M, Nakayama K, Shamima Y, Katagiri A, Iida K, Nakayama N, Miyazaki K: [Two cases of endometrial stromal sarcoma (ESS) in which survival was prolonged by administration of MPA]. Gan To Kagaku Ryoho; 2008 May;35(5):857-61
Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It accounts for 0.5% of all uterine corpus malignant tumors and 10% of all malignant non-epithelial tumors.
  • MPA is one effective hormonal treatment for ESS.
  • We describe two cases in which patients with metastatic low-grade ESS lesions had prolonged survival with MPA therapy.
  • Case 1 was a 50-year-old woman with a low-grade uterine endometrial stromal tumor who had been operated on at another hospital.
  • She had an incomplete response to chemotherapy.
  • We initiated MPA therapy, which resulted in significant improvement in her metastatic lesions.
  • Case 2 was a 58-year-old woman with stage Ic low-grade ESS who presented with abnormal uterine bleeding.
  • Following surgery (TAH+BSO), MPA therapy was initiated and she had no recurrence.
  • She was treated with chemotherapy, MPA and radiotherapy.
  • Her metastases improved, and the patient has continued to survive on MPA therapy alone.
  • These cases suggest that MPA might be an effective hormonal therapy for patients with low-grade ESS.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Medroxyprogesterone Acetate / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487930.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


27. Engel J, Hölzel D: [Risk and prognosis of corpus carcinomas after tamoxifen treatment of breast carcinoma]. Strahlenther Onkol; 2001 Jul;177(7):371
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Risk and prognosis of corpus carcinomas after tamoxifen treatment of breast carcinoma].
  • [Transliterated title] Risiko und Prognose von Korpuskarzinomen nach Tamoxifenbehandlund des Mammakarzinoms.
  • Beside of recurrences, radiation effects to the esophagus should be considered if dysphagia after irradiation of thoracic tumors occurs, because, as in this case, therapy may rapidly improve the symptoms.
  • [MeSH-major] Breast Neoplasms / drug therapy. Neoplasms, Second Primary / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Case-Control Studies. Clinical Trials as Topic. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / drug effects. Humans. Neoplasm Staging. Prognosis. Risk. Tumor Suppressor Protein p53 / genetics. Uterus / drug effects. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11505623.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


28. Wang LH, Xiong Y, Li YF, Li JD, Feng YL, Li YJ, Chen C, Chen L: [Clinical analysis of 12 cases of uterine carcinosarcoma]. Ai Zheng; 2008 May;27(5):516-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 12 cases of uterine carcinosarcoma].
  • BACKGROUND & OBJECTIVE: Uterine carcinosarcoma, also known as malignant mixed mullerian tumors, is an uncommon neoplasm that carries a poor prognosis.
  • This study was to analyze the clinical manifestation, diagnosis, treatment and prognosis of this disease.
  • METHODS: Clinical data of 12 uterine carcinosarcoma patients, diagnosed in Cancer Center of Sun Yat-sen University from 1978 to 2004, were analyzed.
  • RESULTS: Of the 12 cases of uterine carcinosarcoma, 2 were in the cervix, 10 in the corpus uteri.
  • Carcinosarcoma in the corpus uteri manifested abnormal vaginal bleeding and postmenstrual bleeding.
  • Eight patients received chemotherapy and 2 received radiotherapy after operation.
  • CONCLUSIONS: Primary surgery is the main treatment for uterine carcinosarcoma.
  • The prognosis of uterine carcinosarcoma is associated with surgicopathologic stage and treatment modalities.
  • [MeSH-major] Carcinosarcoma / surgery. Hysterectomy / methods. Mixed Tumor, Mullerian / surgery. Uterine Cervical Neoplasms / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate


31. Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Müller B, Budczies J, Röske A, Dietel M, Denkert C: Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol; 2009 Jul;135(7):933-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.
  • PURPOSE: Endometrial adenocarcinoma, due to a frequent activation of PI3 K/AKT has been proposed as a candidate neoplasm for the treatment with mTOR inhibitors.
  • RESULTS: p-mTOR expression was associated with nuclear p-4EBP1 expression (P = 0.02), and was more frequent in tumors extending ouside the uterine corpus (P = 0.011).
  • In cultivated PTEN-deficient Ishikawa cells, in addition to an activation of AKT, a phosphorylation of mTOR and 4EBP1 was evident, while PTEN-wild type HEC-1A cells lacked AKT activation but revealed a reduced expression of p-mTOR and p-4EBP1.
  • Based on our results, we suggest that the expression of elements of the mTOR pathway in human tumor tissue should be further evaluated as a possible predictive marker in large-scale clinical studies as well as translational research protocols in clinical studies with mTOR inhibitors.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Phosphoproteins / metabolism. Protein Kinases / metabolism. Sirolimus / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Antibiotics, Antineoplastic / therapeutic use. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Neoplasm Staging. Phosphorylation. Prognosis. TOR Serine-Threonine Kinases. Treatment Outcome. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):184-96 [16412571.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):892-5 [11309338.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):564-75 [15627018.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Aug;287(2):C281-91 [15028555.001]
  • [Cites] Gynecol Oncol. 2006 Mar;100(3):487-94 [16249016.001]
  • [Cites] Int J Gynecol Cancer. 2003 Mar-Apr;13(2):197-203 [12657124.001]
  • [Cites] Prostate. 2006 Aug 1;66(11):1203-12 [16652388.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):242-56 [16436330.001]
  • [Cites] Cancer Treat Rev. 2007 Apr;33(2):177-90 [17196749.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7551-5 [17699757.001]
  • [Cites] Oncogene. 2006 Oct 16;25(48):6436-46 [17041628.001]
  • [Cites] Cell Cycle. 2007 Jan 1;6(1):65-9 [17245113.001]
  • [Cites] Mol Cancer Ther. 2003 Aug;2(8):789-95 [12939469.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4795-9 [17699857.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1758-64 [11410517.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):292-9 [16443261.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1801-11 [16983702.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23 ):10669-73 [16322209.001]
  • [Cites] Mol Cell. 2005 Apr 15;18(2):143-5 [15837416.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6779-88 [15501954.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):81-9 [17200342.001]
  • [Cites] Biochem J. 1999 Dec 1;344 Pt 2:427-31 [10567225.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19107520.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antibiotics, Antineoplastic; 0 / Biomarkers, Tumor; 0 / EIF4EBP1 protein, human; 0 / Phosphoproteins; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


32. Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr: Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst; 2004 Jan 7;96(1):70-4
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer.
  • Recent studies have indicated that the tamoxifen-related risk of uterine corpus cancer may be especially high for some uncommon cell types, although the magnitude of risk has not been quantified.
  • We evaluated data from 39 451 breast cancer patients diagnosed from 1980 through 2000 who were initially treated with tamoxifen and found that the overall risk of subsequent uterine corpus cancer was increased more than twofold (observed-to-expected ratio [O/E] = 2.17, 95% confidence interval [CI] = 1.95 to 2.41) relative to the general SEER population.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Estrogen Receptor Modulators / adverse effects. Mixed Tumor, Mullerian / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adult. Aged. Carcinoma, Ductal / drug therapy. Confidence Intervals. Female. Humans. Middle Aged. Odds Ratio. Risk Assessment. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14709741.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


33. Fles R, Hoogendoorn WE, Platteel I, Scheerman CE, de Leeuw-Mantel G, Mourits MJ, Hollema H, van Leeuwen FE, van Boven HH, Nederlof PM: Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. Genes Chromosomes Cancer; 2010 Aug;49(8):699-710
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tamoxifen has been a very effective treatment for breast cancer for several decades, however, at the same time increases the risk of endometrial cancer, especially after prolonged exposure.
  • In addition, tamoxifen has been associated with a higher proportion of unfavorable uterine tumor subtypes (carcinosarcomas and serous adenocarcinomas) with worse survival.
  • We investigated whether endometrial tumors, which developed after prolonged tamoxifen treatment for breast cancer, are genetically different from endometrial tumors without preceding tamoxifen exposure.
  • Genomic profiles were correlated with tamoxifen exposure, tumor subtypes, and histopathological characteristics of the endometrial tumors.
  • The common uterine corpus cancers of the endometrioid subtype show few genomic aberrations.
  • Tumors that developed after prolonged tamoxifen use did not show more or different aberrations than unexposed tumors.
  • This was true for all tumor subtypes.
  • Thus, endometrial carcinomas that develop after prolonged tamoxifen use cannot be distinguished from nonusers on basis of their tumor genomic profile.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Endometrial Neoplasms / genetics. Gene Expression Profiling. Neoplasms, Second Primary. Tamoxifen / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Aged. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinosarcoma / drug therapy. Carcinosarcoma / genetics. Carcinosarcoma / pathology. Case-Control Studies. Chromosome Aberrations. Comparative Genomic Hybridization. Female. Humans. Immunoenzyme Techniques. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20544844.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


34. Gallardo A, Prat J: Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol; 2009 Feb;33(2):278-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian adenosarcomas are rare mixed tumors of low malignant potential that occur mainly in the uterus and also in extrauterine locations.
  • Thirty-seven tumors were of the uterine corpus, 11 of the cervix, 4 of the ovary, and 1 each of the fallopian tube, vagina, and Douglas peritoneum.
  • Treatment was known in 50 patients: 10 had polypectomy, 1 cone biopsy, and 39 hysterectomy, which was accompanied by bilateral salpingo-oophorectomy in 24 and lymphadenectomy in 4.
  • Five patients had radiotherapy and 2 of them had chemotherapy.
  • Of 30 tumors of the uterine corpus, 17 were stage IA, 11 stage IB, 1 stage IC, and 1 stage IIIC.
  • The tumor of the fallopian tube was stage IC, and the tumors of the vagina and recto-uterine pouch were confined to their site of origin.
  • Most uterine tumors were polypoid masses ranging from 1 to 20 cm (mean: 6.5 cm).
  • Fourteen of 30 uterine tumors (47%) had myometrial invasion that was minimal in 5, involved one-third of the myometrial thickness in 7, and more than 50% in 2.
  • Six developed metastases and 5 of them died of tumor.
  • Four had adenosarcomas with sarcomatous overgrowth; however, the other 2 patients had typical low-grade adenosarcomas of the uterine corpus and cervix, respectively, exhibiting only mild nuclear atypia of the stromal component and </=2 mitotic figures/10 high power fields.
  • The finding of such cases, which raises the controversy of whether or not adenofibroma exists as a tumor entity, prompted us to make a comparative immunohistochemical analysis of 23 typical adenosarcomas, 8 adenosarcomas with sarcomatous overgrowth, and 29 benign and malignant related lesions, including 7 clinically benign adenofibromas.
  • Adenosarcomas with sarcomatous overgrowth showed strong immunoreaction for Ki-67 and p53 and loss of CD10 and progesterone receptors immunostaining; in contrast, the immunoreaction for these tumor markers in typical adenosarcomas without sarcomatous overgrowth was similar to that of adenofibromas associated with favorable outcome and other benign lesions such as endometrial polyps and endometriosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Mitotic Index. Neoplasm Staging. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941402.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Sadarangani A, Kato S, Espinoza N, Lange S, Llados C, Espinosa M, Villalón M, Lipkowitz S, Cuello M, Owen GI: TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis; 2007 Jan;12(1):73-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer of the reproductive tract encompasses malignancies of the uterine corpus, cervix, ovary, Fallopian tube, among others and accounts for 15% of female cancer mortalities.
  • Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) mediates apoptosis by binding to death receptors and offers a promising cancer treatment.
  • These results suggest that TRAIL may be an effective treatment for endometrial cancer and other female reproductive cancers, with minimal secondary effects on healthy tissue.
  • [MeSH-major] Apoptosis / drug effects. Genital Neoplasms, Female / drug therapy. Genital Neoplasms, Female / pathology. Genitalia, Female / drug effects. TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Cells, Cultured. DNA, Complementary / genetics. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Endometrial Neoplasms / physiopathology. Endometrium / cytology. Endometrium / drug effects. Endometrium / physiology. Female. Humans. Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand / physiology. Recombinant Proteins / pharmacology. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Apoptosis. 2007 Feb;12(2):463
  • (PMID = 17136491.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / GR071469
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human
  •  go-up   go-down


36. Mori H, Niwa K, Zheng Q, Yamada Y, Sakata K, Yoshimi N: Cell proliferation in cancer prevention; effects of preventive agents on estrogen-related endometrial carcinogenesis model and on an in vitro model in human colorectal cells. Mutat Res; 2001 Sep 1;480-481:201-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some oriental herbal medicines like Glycyrrhizae radix or Juzen-taiho-to were found to suppress estradiol-17 beta (E2)-induced expression of c-fos/jun in uterine corpus and inhibited N-methyl-N-nitrosourea and E2-induced endometrial carcinogenesis in mice.
  • It is suggested that the effects of such oriental drugs are exerted probably through suppression of estrogen-induced c-fos/jun expression and they are promising preventing agents for endometrial cancers.
  • The results suggest a mode of action of these chemopreventive agents and also imply that such in vitro short term assay is useful for detection of new agents for cancer prevention.
  • [MeSH-major] Adenocarcinoma / prevention & control. Antineoplastic Agents, Phytogenic / pharmacology. Colorectal Neoplasms / drug therapy. Drugs, Chinese Herbal / pharmacology. Endometrial Neoplasms / prevention & control
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Division / drug effects. Cell Line. Chemoprevention. Disease Models, Animal. Estradiol. Female. Glycyrrhiza / chemistry. Humans. Hyperplasia / chemically induced. Hyperplasia / pathology. Hyperplasia / prevention & control. Methylnitrosourea. Mice. Mice, Inbred ICR. Plants, Medicinal. Proto-Oncogene Proteins c-fos / genetics. Proto-Oncogene Proteins c-fos / metabolism. Proto-Oncogene Proteins c-jun / genetics. Proto-Oncogene Proteins c-jun / metabolism. RNA, Messenger / metabolism. Tumor Cells, Cultured. Uterus / drug effects. Uterus / metabolism. Uterus / pathology






Advertisement